924869-27-2

Basic information

• Product Name: TERT-BUTYL 2,4,6,7-TETRAHYDRO-5H-PYRAZOLO[4,3-C]PYRIDINE-5-CARBOXYLATE
• Synonyms: TERT-BUTYL 2,4,6,7-TETRAHYDRO-5H-PYRAZOLO[4,3-C]PYRIDINE-5-CARBOXYLATE;2,4,6,7-Tetrahydro-5H-pyrazolo[4,3-c]pyridine, N5-BOC protected;tert-Butyl 6,7-dihydro-2H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate;tert-butyl 2H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-5- carboxylate;tert-Butyl 2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate, 5-(tert-Butoxycarbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine;5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 2,4,6,7-tetrahydro-, 1,1-dimethylethyl ester
• CAS NO: 924869-27-2
• Molecular Formula: C₁₁H₁₇N₃O₂
• Molecular Weight: 223.27158
• Mol File: 924869-27-2.mol

Chemical Properties

• Melting Point: 127-128°C
• Boiling Point: 388.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.200±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.99±0.20(Predicted)
• CAS DataBase Reference: TERT-BUTYL 2,4,6,7-TETRAHYDRO-5H-PYRAZOLO[4,3-C]PYRIDINE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 2,4,6,7-TETRAHYDRO-5H-PYRAZOLO[4,3-C]PYRIDINE-5-CARBOXYLATE(924869-27-2)
• EPA Substance Registry System: TERT-BUTYL 2,4,6,7-TETRAHYDRO-5H-PYRAZOLO[4,3-C]PYRIDINE-5-CARBOXYLATE(924869-27-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 924869-27-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
TERT-BUTYL 2,4,6,7-TETRAHYDRO-5H-PYRAZOLO[4,3-C]PYRIDINE-5-CARBOXYLATE is used as a key intermediate in the synthesis of various drug candidates due to its unique chemical structure and potential therapeutic properties.
Used in the Synthesis of Anticonvulsant Agents:
In the pharmaceutical industry, TERT-BUTYL 2,4,6,7-TETRAHYDRO-5H-PYRAZOLO[4,3-C]PYRIDINE-5-CARBOXYLATE is used as a precursor for developing anticonvulsant medications, leveraging its potential to treat seizure disorders.
Used in the Development of Analgesic Medications:
TERT-BUTYL 2,4,6,7-TETRAHYDRO-5H-PYRAZOLO[4,3-C]PYRIDINE-5-CARBOXYLATE is also utilized in the creation of analgesic drugs, capitalizing on its analgesic properties to provide pain relief in various clinical settings.
Used in Medicinal Chemistry:
TERT-BUTYL 2,4,6,7-TETRAHYDRO-5H-PYRAZOLO[4,3-C]PYRIDINE-5-CARBOXYLATE serves as a versatile building block in medicinal chemistry, facilitating the design and synthesis of new compounds with improved pharmacological profiles.

Upstream product

• 1310796-19-0 (Z)-3-((dimethylamino)methylene)-4-oxopiperidine-1-carboxylic acid tert-butyl ester 
• 1202645-17-7 3-dimethylaminomethylene-4-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 157327-41-8 t-butyl-3-[(dimethylamino)methylidene]-4-oxopiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 100501-57-3 tert-butyl 2-methyl-6,7-dihydro-2H-pyrazolo(4,3-c)pyridine-5(4H)-carboxylate 
• 100501-58-4 1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine 
• 1373223-68-7 4,5,6,7-tetrahydro-2-(3-pyridinyl)-2H-pyrazolo[4,3-c]pyridine 
• 1258976-24-7 1,1-dimethylethyl 2-(5-{3-cyano-4-[(1-methylethyl)oxy]-phenyl}-1,3,4-thiadiazol-2-yl)-2,4,6,7-tetrahydro-5H-pyrazolo-[4,3-c]pyridine-5-carboxylate 
• 949962-96-3 2-cyclopentyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine 
• 949922-59-2 tert-butyl 2-cyclopentyl-6,7-dihydro-2H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate 

Relevant articles and documents

Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold

A series of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold were identified with good cellular and human whole blood activity against IDO1. These inhibitors contain multiple chiral centers and all diastereomers were separated. The absolute stereochemistry of each isomers were not determined. Compounds 15 and 27 stood out as leads due to their good cellular as well as human whole blood IDO1 inhibition activity, low unbound clearance, and reasonable mean residence time in rat cassette PK studies.

ANNULATED GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W1, W2, W3, W4, W5, W6, L, Q, Rx and u have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

Compound as potassium channel modulator

The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.

BICYCLIC BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION

The present invention relates to certain bicyclic bis-heteroaryl compounds of Formula (I), pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and

BICYCLIC PYRAZOLE PESTICIDES

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, (1) wherein Q is (Q-1) or (Q-2); and A, R1, m, X1, X1a, X1b, X2, R2, R5, q and t are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof:wherein Y1 is of formula (?) or formula (y):Ring Y is a 5- to 6-membered heteroaryl ring; and V4, V5, Rx, x, y, and n are as defined herein. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

Calcitonin gene related peptide receptor antagonists

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS

The presnt invention relates to compounds of Formula (I), as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.